Form 6-K Galmed Pharmaceuticals For: Aug 25
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- S&P 500 and Nasdaq end higher on cool inflation data, solid bank earnings
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- Fed’s Warsh says central bank won’t tolerate high inflation
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
- IBM misses Q2 targets as mainframe and software sales disappoint
- Verizon planning new round of layoffs this week - Barron’s
- Goldman Sachs Upgrades NIO (NIO) to Buy
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
Galmed Pharmaceuticals terminates licensing deal, plans minority stake
August 25, 2025 8:16 AM EDTGalmed Pharmaceuticals Ltd. (NASDAQ: GLMD) terminated a licensing agreement with Entomus s.r.o. for development and commercialization of a Self-Emulsifying Drug Delivery System formulation, according to a company statement.
The pharmaceutical company ended the binding term sheet following additional due diligence and... More
Galmed Pharmaceuticals terminates licensing deal, plans minority stake
August 25, 2025 7:41 AM EDTGalmed Pharmaceuticals Ltd. (NASDAQ: GLMD) terminated a licensing agreement with Entomus s.r.o. for development and commercialization of a Self-Emulsifying Drug Delivery System formulation, according to a company statement.
The pharmaceutical company ended the binding term sheet following additional due diligence and... More
